Dana Blankenhorn

Dana Blankenhorn

InvestorPlace Contributor

Expertise: Technology, Biotech, Renewable energy

Education: M.S,J. Northwestern (Medill School) 1978; B.A. Rice University, History and Political Science 1977

Awards & Accomplishments: Tech reporter since 1982, Freelance since 1983, on Internet since 1985. Created first online coverage of Internet with a magazine, Interactive Age, 1994 Co-wrote BBS Systems for Business in 1991, Wrote Guide to Field Computing in 1992 Wrote technology history now called "Living with Moore's Law" in 2001, 2010, 2021 Author of over a dozen books, both fiction and non-fiction

About Dana:
Dana Blankenhorn has been a financial journalist since 1978, a technology journalist since 1982, and an Internet journalist since 1985. He writes a Substack newsletter, Facing the Future, which covers technology, markets, and politics.

He has written a half-dozen technology books, several novels available at the Amazon Kindle store, and covered beats ranging from education to e-commerce, and from open source to renewable energy. He lives in Atlanta.

Recent Articles

Sorrento Stock: Gambling on Coronavirus

By Dana Blankenhorn, InvestorPlace Contributor

Few companies are in all the major Covid-19 sectors, but Sorrento has made claims for a test, a vaccine and a cure. This brought many eyes to SRNE stock.

Once Slow, Stable Sanofi Stock is Now Pharma’s Most-Talked About Name

By Dana Blankenhorn, InvestorPlace Contributor

SNY stock is no longer a sleepy passive investment. Under a new CEO, Sanofi is less reliant on diabetes and heart drugs and looking to buy pre-market cancer blockbusters.

5 Election Stocks for a Biden Presidency

By Dana Blankenhorn, InvestorPlace Contributor

Biden supports renewable energy, manufacturers and a strong banking sector. That's why investors will want to watch these election stocks as November approaches.

Regeneron Stock Is a Play For Covid-19, And More

By Dana Blankenhorn, InvestorPlace Contributor

Regeneron is trialing a cocktail of antibodies that may treat Covid-19 and prevent illness for people routinely exposed.

Investors Should View IBIO Stock Among Vaccine Wanna-be’s, Not Makers

By Dana Blankenhorn, InvestorPlace Contributor

IBIO stock has been acting like a potential COVID-19 vaccine producer, but it lacks contracts with leading providers and its own work remains at a pre-clinical stage.

Load More